International Alliance for Personalised Medicine (IPM) shared a post on LinkedIn:
“The Greatest Inequality in Healthcare Isn’t Disease. It’s Access.
Access to healthcare is often discussed as a policy issue. In reality, it is a matter of outcomes, opportunity, and dignity.
Where a person lives, their income, or the healthcare system they happen to be born into should not determine whether they receive an early diagnosis, access to innovative treatments, or the best possible chance of living a healthy life.
Yet across Europe and around the world, major disparities remain.
In oncology, patients can face significant differences in access to molecular diagnostics, precision therapies, and clinical trials.
In neurology, delayed diagnosis and unequal access to specialist care can have life-changing consequences for people living with conditions such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
In cardiovascular and cardiometabolic diseases, prevention, screening, and access to innovative treatments can dramatically influence long-term outcomes and quality of life. In eye health, early detection and timely intervention are often the difference between preserving sight and irreversible vision loss.
The good news is that science is advancing rapidly.
Personalised medicine, genomics, artificial intelligence, digital health technologies, and data-driven healthcare are creating unprecedented opportunities to deliver more precise, effective, and patient-centred care. But innovation alone is not enough. If access remains unequal, innovation risks widening existing health disparities rather than reducing them.
At the International Alliance for Personalised Medicine (IPM), we believe that every patient should have the opportunity to benefit from medical progress, regardless of geography, socioeconomic status, or disease area.
The challenge is no longer whether we can innovate. The challenge is ensuring that innovation reaches everyone who needs it.
Quality healthcare should not be a privilege, but a reality for all.”
Other articles from IPM on OncoDaily.